Journal
FRONTIERS IN AGING NEUROSCIENCE
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2019.00057
Keywords
Parkinson's disease; voxel-based morphometry; voxel-based quantification; covariance analysis; symptoms severity
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research
- Abbvie
- Avid Radiopharmaceuticals
- Biogen Idec
- Briston-Myers Squibb
- Covance
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lilly
- Lundbeck
- Merck
- Meso Scale Discovery
- Pfizer
- Piramal
- Roche
- UCB
- National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust
- Henry Smith Charity
- Action Medical Research [GN2214]
- Swiss National Science Foundation [32003B_159780, SPUM 33CM30_140332/1]
- Foundation Parkinson Switzerland
- Foundation Synapsis
- Roger de Spoelberch Foundation
- Partridge Foundation
- Swiss National Science Foundation (SNF) [32003B_159780] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
There is an increasing interest in identifying non-invasive biomarkers of disease severity and prognosis in idiopathic Parkinson's disease (PD). Dopamine-transporter SPECT (DAT-SPECT), diffusion tensor imaging (DTI), and structural magnetic resonance imaging (sMRI) provide unique information about the brain's neurotransmitter and microstructural properties. In this study, we evaluate the relative and combined capability of these imaging modalities to predict symptom severity and clinical progression in de novo PD patients. To this end, we used MRI, SPECT, and clinical data of de novo drug-naive PD patients (n = 205, mean age 61 +/- 10) and age-, sex-matched healthy controls (n = 105, mean age 58 +/- 12) acquired at baseline. Moreover, we employed clinical data acquired at 1 year follow-up for PD patients with or without L-Dopa treatment in order to predict the progression symptoms severity. Voxel-based group comparisons and covariance analyses were applied to characterize baseline disease-related alterations for DAT-SPECT, DTI, and sMRI. Cortical and subcortical alterations in de novo PD patients were found in all evaluated imaging modalities, in line with previously reported midbrain-striato-cortical network alterations. The combination of these imaging alterations was reliably linked to clinical severity and disease progression at 1 year follow-up in this patient population, providing evidence for the potential use of these modalities as imaging biomarkers for disease severity and prognosis that can be integrated into clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available